Plus Therapeutics, Inc. (PSTV)Healthcare | Biotechnology | Houston, United States | NasdaqCM
6.39 USD
+0.44
(7.395%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.38 -0.01 (-0.010%) ⇩ (April 17, 2026, 7:51 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:34 p.m. EDT
Violent short-term downtrend and zero fundamental upside make PSTV uninvestable for capital preservation; immediate put opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.169828 |
| AutoETS | 0.172860 |
| AutoARIMA | 0.172861 |
| AutoTheta | 0.277393 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 20% |
| H-stat | 18.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 0.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 20.546 |
| Revenue per Share | 1.675 |
| Market Cap | 43,848,352 |
| Forward P/E | -2.71 |
| Beta | 1.02 |
| Website | https://plustherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.60062504 |
| Address1 | 6,420 LEVIT GREEN BOULEVARD |
| Address2 | SUITE 210 |
| All Time High | 28,153,124.0 |
| All Time Low | 2.9 |
| Ask | 5.95 |
| Ask Size | 1 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 854,050 |
| Average Daily Volume3 Month | 430,342 |
| Average Volume | 430,342 |
| Average Volume10Days | 854,050 |
| Beta | 1.023 |
| Bid | 5.86 |
| Bid Size | 2 |
| Book Value | 0.72 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.39 |
| Current Ratio | 1.232 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.4399 |
| Day Low | 5.7638 |
| Debt To Equity | 20.546 |
| Display Name | Plus Therapeutics |
| Dividend Date | 1,565,049,600 |
| Earnings Call Timestamp End | 1,743,109,200 |
| Earnings Call Timestamp Start | 1,743,109,200 |
| Earnings Timestamp End | 1,772,658,000 |
| Earnings Timestamp Start | 1,772,658,000 |
| Ebitda | -14,853,000 |
| Ebitda Margins | -2.84922 |
| Enterprise To Ebitda | -2.428 |
| Enterprise To Revenue | 6.917 |
| Enterprise Value | 36,057,360 |
| Eps Current Year | -3.8175 |
| Eps Forward | -2.355 |
| Eps Trailing Twelve Months | -7.25 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 210 974 6901 |
| Fifty Day Average | 6.1706 |
| Fifty Day Average Change | 0.21939993 |
| Fifty Day Average Change Percent | 0.035555687 |
| Fifty Two Week Change Percent | -60.062504 |
| Fifty Two Week High | 30.5 |
| Fifty Two Week High Change | -24.11 |
| Fifty Two Week High Change Percent | -0.7904918 |
| Fifty Two Week Low | 2.9 |
| Fifty Two Week Low Change | 3.4899998 |
| Fifty Two Week Low Change Percent | 1.2034482 |
| Fifty Two Week Range | 2.9 - 30.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 994,858,200,000 |
| Float Shares | 6,325,074 |
| Forward Eps | -2.355 |
| Forward P E | -2.7133758 |
| Free Cashflow | -13,597,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 28 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.60733 |
| Gross Profits | -3,166,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01451 |
| Held Percent Institutions | 0.14019 |
| Implied Shares Outstanding | 6,862,027 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,775,088,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas. |
| Long Name | Plus Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 43,848,352 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_264193 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -22,386,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 43,779,732 |
| Number Of Analyst Opinions | 4 |
| Open | 6.01 |
| Operating Cashflow | -20,775,000 |
| Operating Margins | -4.20044 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.45 |
| Phone | 737 255 7194 |
| Post Market Change | -0.009999752 |
| Post Market Change Percent | -0.15649064 |
| Post Market Price | 6.38 |
| Post Market Time | 1,776,469,898 |
| Previous Close | 5.95 |
| Price Eps Current Year | -1.6738702 |
| Price Hint | 2 |
| Price To Book | 8.874999 |
| Price To Sales Trailing12 Months | 8.411347 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.726 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | 0.44 |
| Regular Market Change Percent | 7.39496 |
| Regular Market Day High | 6.4399 |
| Regular Market Day Low | 5.7638 |
| Regular Market Day Range | 5.7638 - 6.4399 |
| Regular Market Open | 6.01 |
| Regular Market Previous Close | 5.95 |
| Regular Market Price | 6.39 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 253,258 |
| Return On Assets | -0.83292997 |
| Revenue Growth | -0.032 |
| Revenue Per Share | 1.675 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,862,027 |
| Shares Percent Shares Out | 0.13949999 |
| Shares Short | 957,308 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 806,285 |
| Short Name | PLUS THERAPEUTICS, Inc. |
| Short Percent Of Float | 0.1401 |
| Short Ratio | 5.14 |
| Source Interval | 15 |
| State | TX |
| Symbol | PSTV |
| Target High Price | 65.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 38.0 |
| Target Median Price | 37.5 |
| Total Cash | 8,612,000 |
| Total Cash Per Share | 1.255 |
| Total Debt | 821,000 |
| Total Revenue | 5,213,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.3014 |
| Two Hundred Day Average Change | -4.9114003 |
| Two Hundred Day Average Change Percent | -0.43458334 |
| Type Disp | Equity |
| Volume | 253,258 |
| Website | https://plustherapeutics.com |
| Zip | 77,021 |